AJMC December 9, 2024
Key Takeaways
- GLP-1 agonists, like semaglutide and tirzepatide, target the gut-brain axis, offering significant benefits in obesity management by mimicking gut hormones.
- Imaging advancements, including CAC scoring and CCTA, enable early detection of coronary plaque, with AI enhancing analysis and prediction of atherosclerosis progression.
- Patients with autoimmune diseases face increased cardiovascular risks; advanced imaging and emerging therapies targeting inflammation are crucial for early detection and management.
- The debate on Lp(a) testing in primary prevention highlights differing views on its actionability, with considerations of healthcare system limitations and testing costs.
The top 5 most-viewed content from this year’s American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease (CVD) Prevention included interviews with Robert Kushner, MD, MS, and Martha...
Today's Sponsors
Today's Sponsor